Pfizer on schedule to consolidate Enbrel franchise as ozoralizumab hits RA endpoint
This article was originally published in Scrip
Executive Summary
Pfizer's bid to maintain the franchise of its rheumatoid arthritis blockbuster Enbrel's took another step when Ablynx, Pfizer's Belgium-based licensor announced top-line results of Pfizer's phase II clinical trial of ozoralizumab in rheumatoid arthritis. If ozoralizumab (ATN-103), an anti-TNF-alpha nanobody, match Enbrel in the clinic, its cost-of-good advantage might not only help Pfizer fight its corner against other branded TNF-inhibitors, but also repel the onslaught of biosimilar manufacturers that will emerge as Enbrel starts to come of patent in 2012.